You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,985,548


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,985,548
Title:Materials and methods directed to asparagine synthetase and asparaginase therapies
Abstract: Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.
Inventor(s): Lorenzi; Philip L. (Washington, DC), Weinstein; John N. (Bellaire, TX), Caplen; Natasha J. (Silver Spring, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:12/281,589
Patent Claims:1. A method of screening for the efficacy of L-asparaginase (L-ASP) in a subject, the method comprising: (a) detecting a level of expression of an endogenous asparagine synthetase (ASNS) gene protein product in a sample from the subject, wherein the level is associated with an efficacy of L-asparaginase in decreasing cell proliferation, and (b) identifying the efficacy based on the level of expression.

2. The method of claim 1, wherein the level is low compared to a chosen standard and the low level is associated with an increased efficacy of L-asparaginase in decreasing cell proliferation.

3. The method of claim 1, wherein the level is high compared to a chosen standard and the high level is associated with a decreased efficacy of L-asparaginase in decreasing cell proliferation.

4. The method of claim 1, wherein the sample comprises cancer cells and the detecting the level of expression of ASNS protein comprises incubating the sample with a first antibody that specifically binds ASNS protein and a second antibody that binds the first antibody and allows for staining of the sample.

5. The method of claims 1, wherein the sample is screened for the level of expression of a second gene associated with efficacy of L-ASP.

6. The method of claim 1, the method further comprising administering an ASNS inhibitor.

7. The method of claim 1, the method further comprising administering L-ASP to the subject based on an identification of an increased efficacy for treatment with L-ASP.

8. The method of claim 1, wherein the subject possesses one or more characteristics from the group consisting of a p53 mutation, altered HER-2/neu expression, altered EGFR expression, CD10 negativity, MLL gene rearrangements, carboplatin sensitivity, taxane resistance, adriamycin resistance, and any combination thereof.

9. The method of claim 1, wherein the subject has been diagnosed with a disorder associated with low ASNS expression.

10. The method of claim 1, wherein the subject has been diagnosed with a cancer or an increased susceptibility for a cancer.

11. The method of claim 10, wherein the cancer is a tumor.

12. The method of claim 10, wherein the cancer is a cancer selected from the group consisting of leukemia, an ovarian cancer, a pancreatic cancer, a glioblastoma, a renal cancer, a melanoma, a breast cancer, a head and neck cancer, and any combination thereof

13. The method of claim 12, wherein the ovarian cancer is an ovarian adenocarcinoma.

14. The method of claim 12, wherein the pancreatic cancer is a pancreatic adenocarcinoma.

15. The method of claim 12, wherein the renal cancer is a clear cell renal carcinoma.

16. The method of claim 12, wherein the breast cancer is an estrogen receptor negative breast cancer.

17. The method of claim 1, wherein the subject is human.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.